Sweden's Ascelia Pharma Q2 operating loss narrows
Sweden's Ascelia Pharma Q2 operating loss narrows
Overview
Sweden biotech firm's Q2 operating loss narrowed yr/yr
Company reduced negative cash flow from operations compared to last year
After Q2, company received FDA Complete Response Letter for Orviglance and implemented cost-saving measures
Outlook
Company to meet FDA on Sep 9, 2026, to discuss Orviglance regulatory path
Ascelia Pharma implementing cost-saving measures to reduce cash burn after FDA CRL
Company to provide updates as it gains clarity on Orviglance regulatory path
Result Drivers
REGULATORY FOCUS - Co prioritized finalizing FDA review of Orviglance and preparing for potential partnering during Q2
COST REDUCTIONS - Following FDA Complete Response Letter, co implemented cost-saving measures to reduce cash burn and strengthen liquidity
Company press release: ID:nMFN4NHn41
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| SEK 0.09 |
|
Q2 Cash Flow From Operations |
| -SEK 14 mln |
|
Q2 EBIT |
| -SEK 12.10 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for Ascelia Pharma AB is SEK4.85, about 781.8% above its August 19 closing price of SEK0.55
The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 14 three months ago
Reuters Recommended Reads
Aug 20 - Finland's Nanoform Q2 EBITDA loss narrows on layoffs, cost cuts
Aug 19 - Sweden's Cantargia narrows H1 loss, raises SEK 132 mln
Aug 19 - Denmark's Lundbeck Q2 revenue rises 7% driven by Vyepti and Rexulti
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)